» Articles » PMID: 28924803

Patient-derived Xenografts As Preclinical Neuroblastoma Models

Overview
Journal Cell Tissue Res
Date 2017 Sep 20
PMID 28924803
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

The prognosis for children with high-risk neuroblastoma is often poor and survivors can suffer from severe side effects. Predictive preclinical models and novel therapeutic strategies for high-risk disease are therefore a clinical imperative. However, conventional cancer cell line-derived xenografts can deviate substantially from patient tumors in terms of their molecular and phenotypic features. Patient-derived xenografts (PDXs) recapitulate many biologically and clinically relevant features of human cancers. Importantly, PDXs can closely parallel clinical features and outcome and serve as excellent models for biomarker and preclinical drug development. Here, we review progress in and applications of neuroblastoma PDX models. Neuroblastoma orthotopic PDXs share the molecular characteristics, neuroblastoma markers, invasive properties and tumor stroma of aggressive patient tumors and retain spontaneous metastatic capacity to distant organs including bone marrow. The recent identification of genomic changes in relapsed neuroblastomas opens up opportunities to target treatment-resistant tumors in well-characterized neuroblastoma PDXs. We highlight and discuss the features and various sources of neuroblastoma PDXs, methodological considerations when establishing neuroblastoma PDXs, in vitro 3D models, current limitations of PDX models and their application to preclinical drug testing.

Citing Articles

Development of a Simple and Reproducible Cell-derived Orthotopic Xenograft Murine Model for Neuroblastoma.

Doyle K, Hassan A, Sutter M, Rodriguez M, Kumar P, Brown E In Vivo. 2024; 38(2):531-538.

PMID: 38418146 PMC: 10905463. DOI: 10.21873/invivo.13471.


Zebrafish tumour xenograft models: a prognostic approach to epithelial ovarian cancer.

Lindahl G, Fjellander S, Selvaraj K, Vildeval M, Ali Z, Almter R NPJ Precis Oncol. 2024; 8(1):53.

PMID: 38413842 PMC: 10899227. DOI: 10.1038/s41698-024-00550-9.


A biobank of pediatric patient-derived-xenograft models in cancer precision medicine trial MAPPYACTS for relapsed and refractory tumors.

Marques Da Costa M, Zaidi S, Scoazec J, Droit R, Lim W, Marchais A Commun Biol. 2023; 6(1):949.

PMID: 37723198 PMC: 10507044. DOI: 10.1038/s42003-023-05320-0.


Adaptation of the Th-MYCN Mouse Model of Neuroblastoma for Evaluation of Disseminated Disease.

Rahavi S, Aletaha M, Farrokhi A, Lorentzian A, Lange P, Maxwell C Int J Mol Sci. 2023; 24(15).

PMID: 37569447 PMC: 10419036. DOI: 10.3390/ijms241512071.


Preclinical Models of Neuroblastoma-Current Status and Perspectives.

Krawczyk E, Kitlinska J Cancers (Basel). 2023; 15(13).

PMID: 37444423 PMC: 10340830. DOI: 10.3390/cancers15133314.


References
1.
Baker L, Tiriac H, Clevers H, Tuveson D . Modeling pancreatic cancer with organoids. Trends Cancer. 2016; 2(4):176-190. PMC: 4847151. DOI: 10.1016/j.trecan.2016.03.004. View

2.
Bate-Eya L, Ebus M, Koster J, den Hartog I, Zwijnenburg D, Schild L . Newly-derived neuroblastoma cell lines propagated in serum-free media recapitulate the genotype and phenotype of primary neuroblastoma tumours. Eur J Cancer. 2013; 50(3):628-37. DOI: 10.1016/j.ejca.2013.11.015. View

3.
Baysan M, Woolard K, Bozdag S, Riddick G, Kotliarova S, Cam M . Micro-environment causes reversible changes in DNA methylation and mRNA expression profiles in patient-derived glioma stem cells. PLoS One. 2014; 9(4):e94045. PMC: 3984100. DOI: 10.1371/journal.pone.0094045. View

4.
Bondarenko G, Ugolkov A, Rohan S, Kulesza P, Dubrovskyi O, Gursel D . Patient-Derived Tumor Xenografts Are Susceptible to Formation of Human Lymphocytic Tumors. Neoplasia. 2015; 17(9):735-741. PMC: 4611072. DOI: 10.1016/j.neo.2015.09.004. View

5.
Braekeveldt N, Wigerup C, Gisselsson D, Mohlin S, Merselius M, Beckman S . Neuroblastoma patient-derived orthotopic xenografts retain metastatic patterns and geno- and phenotypes of patient tumours. Int J Cancer. 2014; 136(5):E252-61. PMC: 4299502. DOI: 10.1002/ijc.29217. View